Insomnia is a prevalent sleep disorder characterized by daytime dysfunction as a result of one or more sleep problems. The treatment of insomnia is highly individualized, and physicians consider multiple factors when selecting an appropriate therapeutic. The primary goal of treatment is to improve patients’ quality of sleep, with minimal next-day side effects. Although generics are entrenched in the insomnia treatment algorithm, new therapies have launched in the U.S. market, such as the dual orexin receptor antagonists Belsomra (Merck) and Dayvigo (Eisai), and the pipeline is becoming increasingly active.
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed insomnia patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed insomnia patients?
- How have Belsomra and Dayvigo been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of insomnia patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of insomnia patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Geographies: United States
Real-world data: Longitudinal patient-level claims data analysis
Key drugs covered: Belsomra, Dayvigo, zolpidem IR, zolpidem CR, eszopiclone, trazodone, Rozerem, ramelteon, zaleplon, doxepin, BZDs
Key analysis provided:
- Brand/therapy usage across longitudinal patient sample.
- Newly diagnosed patient analysis.
- Treatment initiation and progression.
- Line of therapy analysis.
- Combination therapy analysis.
- Source of business for recently treated patients.
- Persistency and compliance analysis.
- Product-level patient flowcharts.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.